Leerink Partnrs Predicts Stronger Earnings for Cencora

Cencora, Inc. (NYSE:COR) – Research analysts at Leerink Partnrs increased their FY2026 earnings estimates for shares of Cencora in a report released on Wednesday, November 6th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings per share of $17.08 for the year, up from their previous forecast of $16.44. The consensus estimate for Cencora’s current full-year earnings is $14.86 per share.

Other equities research analysts have also issued reports about the stock. Wells Fargo & Company lifted their price target on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. Evercore ISI lifted their price target on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Robert W. Baird lifted their price target on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Barclays lifted their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $271.20.

Cencora Price Performance

COR stock opened at $248.41 on Monday. The firm has a market cap of $48.95 billion, a P/E ratio of 33.08, a P/E/G ratio of 1.55 and a beta of 0.44. The company has a quick ratio of 0.55, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The company’s 50-day moving average price is $231.95 and its two-hundred day moving average price is $230.74. Cencora has a 12 month low of $191.11 and a 12 month high of $251.00.

Institutional Trading of Cencora

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Trustmark National Bank Trust Department increased its stake in Cencora by 4.8% during the 3rd quarter. Trustmark National Bank Trust Department now owns 5,690 shares of the company’s stock valued at $1,281,000 after purchasing an additional 262 shares in the last quarter. Intech Investment Management LLC increased its stake in Cencora by 12.5% during the 3rd quarter. Intech Investment Management LLC now owns 73,012 shares of the company’s stock valued at $16,434,000 after purchasing an additional 8,091 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Cencora by 4.1% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 357,299 shares of the company’s stock valued at $80,421,000 after purchasing an additional 14,050 shares in the last quarter. Moran Wealth Management LLC increased its stake in Cencora by 4.0% during the 3rd quarter. Moran Wealth Management LLC now owns 76,490 shares of the company’s stock valued at $17,216,000 after purchasing an additional 2,976 shares in the last quarter. Finally, Portfolio Design Labs LLC bought a new stake in shares of Cencora in the 3rd quarter worth $1,404,000. Institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 15.80% of the stock is owned by corporate insiders.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date is Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is presently 27.16%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.